Roxatidine

Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is an orally active histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect. Roxatidine is promising for research of gastric and duodenal ulcers[1][2][3].

Product Specifications

CAS Number

[78273-80-0]

UNSPSC

12352005

Hazard Statement

H302

Target

Caspase; Histamine Receptor; NF-κB; p38 MAPK

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Neuronal Signaling; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/roxatidine.html

Purity

98.25

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NCCCOC1=CC=CC(CN2CCCCC2)=C1)CO

Molecular Formula

C17H26N2O3

Molecular Weight

306.41

Precautions

H302

References & Citations

[1]Lee M, et al. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation. Sci Rep. 2017;7:41721. Published 2017 Jan 31. |[2]Collins JD, et al. Pharmacokinetics of roxatidine in healthy volunteers. Drugs. 1988;35 Suppl 3:41-7. |[3]Cho EJ, et al. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112 (12) :3648-59.